How COVID has changed our lives, 5 years later
The big picture: The virus upended our daily lives. It sent us into quarantine, closed our offices and schools, introduced us to the N95 mask, and for a time seemed to transform every face-to-face interaction into a potentially fatal health risk.
Catch up quick: Saturday marks the five-year anniversary of Walz's order sending home nearly 1 million K–12 students — the second in a series of escalating directives in response to the spreading virus.
On March 19, health officials confirmed Minnesota's first COVID death. Less than a week later, Walz signed the first "stay at home" order.
State of play: COVID itself remains in our lives. In the last year, the virus hospitalized more than 18,000 Minnesotans and killed 777 people — almost ten times more deaths than influenza caused.
Beyond that, readers say the pandemic still shapes their lives.
What you're saying:"In hindsight, I choose to be thankful," reader Julie J. wrote us.
"I got COVID but I got better," she said. "I had a white-collar job so I could transition to working at home pretty easily — unlike so many frontline workers who lacked that luxury."
💔 Debra Q. observed that in some families, the pandemic exposed lasting divisions that "set off a continuing litany of differences."
Strain over "COVID, vaccines in general, immigration, abortion, climate change, etc. [is] all part of the family dynamic now," she wrote.
🏡 Wendy M. "became a total introvert who loves being home."
Wendy also quit drinking during the first winter wave. "Four years' sobriety," she wrote, "but my anxiety is off the charts."
The pandemic even altered how she shops: "I'm still hoarding more of the things we ran out of — just in case. I'll never run out of essentials (like toilet paper, masks, M&Ms, etc.) again."
🎙 Kerri A. changed careers, moving into voice acting — which she now does entirely from home.
🚛 Ruth J. decided to retire from teaching and move to Minnesota to be closer to family.
"Now we attend every concert, basketball game, play, and school event our grands are in," she said.
🙏 Julie J. started playing trivia online during lockdown and still meets in person with the same team.
Looking back, she said, "I know I was one of the lucky ones."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
COVID, flu, RSV: how these common viruses are tracking this winter – and how to protect yourself
Winter is here, and with it come higher rates of respiratory illnesses. If you've been struck down recently with a sore throat, runny nose and a cough, or perhaps even a fever, you're not alone. Last week, non-urgent surgeries were paused in several Queensland hospitals due to a surge of influenza and COVID cases filling up hospital beds. Meanwhile, more than 200 aged care facilities around Australia are reportedly facing COVID outbreaks. So, just how bad are respiratory infections this year, and which viruses are causing the biggest problems? COVID Until May, COVID case numbers were about half last year's level, but June's 32,348 notifications are closing the gap (compared with 45,634 in June 2024). That said, we know far fewer people test now than they did earlier in the pandemic, so these numbers are likely to be an underestimate. According to the latest Australian Respiratory Surveillance Report, Australia now appears to be emerging from a winter wave of COVID cases driven largely by the NB.1.8.1 subvariant, known as 'Nimbus'. Besides classic cold-like symptoms, this Omicron offshoot can reportedly cause particularly painful sore throats as well as gastrointestinal symptoms such as nausea and diarrhoea. While some people who catch COVID have no symptoms or just mild ones, for many people the virus can be serious. Older adults and those with chronic health issues remain at greatest risk of experiencing severe illness and dying from COVID. Some 138 aged care residents have died from COVID since the beginning of June. The COVID booster currently available is based on the JN.1 subvariant. Nimbus is a direct descendant of JN.1 – as is another subvariant in circulation, XFG or 'Stratus' – which means the vaccine should remain effective against current variants. Free boosters are available to most people annually, while those aged 75 and older are advised to get one every six months. Vaccination, as well as early treatment with antivirals, lowers the risk of severe illness and long COVID. People aged 70 and older, as well as younger people with certain risk factors, are eligible for antivirals if they test positive. Influenza The 2025 flu season has been unusually severe. From January to May, total case numbers were 30% higher than last year, increasing pressure on health systems. More recent case numbers seem to be trending lower than 2024, however we don't appear to have reached the peak yet. Flu symptoms are generally more severe than the common cold and may include high fever, chills, muscle aches, fatigue, sore throat and a runny or blocked nose. Most people recover in under a week, but the flu can be more severe (and even fatal) in groups including older people, young children and pregnant women. An annual vaccination is available for free to children aged 6 months to 4 years, pregnant women, those aged 65+, and other higher-risk groups. Queensland and Western Australia provide a free flu vaccine for all people aged 6 months and older, but in other states and territories, people not eligible for a free vaccine can pay (usually A$30 or less) to receive one. RSV The third significant respiratory virus, respiratory syncytial virus (RSV), only became a notifiable disease in 2021 (before this doctors didn't need to record infections, meaning data is sparse). Last year saw Australia's highest case numbers since RSV reporting began. By May, cases in 2025 were lower than 2024, but by June, they had caught up: 27,243 cases this June versus 26,596 in June 2024. However it looks as though we may have just passed the peak. RSV's symptoms are usually mild and cold-like, but it can cause serious illness such as bronchiolitis and pneumonia. Infants, older people, and people with chronic health conditions are among those at highest risk. In young children, RSV is a leading cause of hospitalisation. A free vaccine is now available for pregnant women, protecting infants for up to six months. A monoclonal antibody (different to a vaccine but also given as an injection) is also available for at-risk children up to age two, especially if their mothers didn't receive the RSV vaccine during pregnancy. For older adults, two RSV vaccines (Arexvy and Abrysvo) are available, with a single dose recommended for everyone aged 75+, those over 60 at higher risk due to medical conditions, and all Aboriginal and Torres Strait Islander people aged 60+. Unfortunately, these are not currently subsidised and cost about $300. Protection lasts at least three years. The common cold While viruses including COVID, RSV and influenza dominate headlines, we often overlook one of the most widespread – the common cold. The common cold can be caused by more than 200 different viruses – mainly rhinoviruses but also some coronaviruses, adenoviruses and enteroviruses. Typical symptoms include a runny or blocked nose, sore throat, coughing, sneezing, headache, tiredness and sometimes a mild fever. Children get about 6–8 colds per year while adults average 2–4, and symptoms usually resolve in a week. Most recover with rest, fluids, and possibly over-the-counter medications. Because so many different viruses cause the common cold, and because these constantly mutate, developing a vaccine has been extremely challenging. Researchers continue to explore solutions, but a universal cold vaccine remains elusive. How do I protect myself and others? The precautions we learned during the COVID pandemic remain valid. These are all airborne viruses which can be spread by coughing, sneezing and touching contaminated surfaces. Practise good hygiene, teach children proper cough etiquette, wear a high-quality mask if you're at high risk, and stay home to rest if unwell. You can now buy rapid antigen tests (called panel tests) that test for influenza (A or B), COVID and RSV. So, if you're unwell with a respiratory infection, consider testing yourself at home. While many winter lurgies can be trivial, this is not always the case. We can all do our bit to reduce the impact. This article is republished from The Conversation. It was written by: Adrian Esterman, University of South Australia Read more: Here's why 3-person embryos are a breakthrough for science – but not LGBTQ+ families Pumped up with poison: new research shows many anabolic steroids contain toxic metals From painkillers to antibiotics: five medicines that could harm your hearing Adrian Esterman receives funding from the Medical Research Future Fund.
Yahoo
18 hours ago
- Yahoo
3 Unstoppable Ultra-High-Yield Stocks to Buy Right Now for Less Than $500
Key Points LTC Properties is offering a 6.4% dividend yield. Omega Healthcare sports a 6.9% yield. Universal Health Realty has a 7.1% yield. 10 stocks we like better than Omega Healthcare Investors › The S&P 500 index (SNPINDEX: ^GSPC) has a miserly dividend yield of just 1.2% today. The average healthcare stock has a yield of just under 1.8%. But what if you could get yields from healthcare stocks that were three to nearly four times higher? You can! Here are three healthcare landlords that have paid reliably and have huge yields, and you can get several shares for less than $500. Surviving the pandemic in one piece When the COVID-19 pandemic hit, nursing homes and senior housing properties got slammed. It makes sense; COVID spread easily in group settings and was particularly deadly for older adults. Occupancy levels fell, move-ins stalled, and move-outs (which include deaths) rose. It was a brutal time for senior housing landlords, with some of the largest and most respected healthcare real estate investment trusts (REITs) cutting their dividends, including Ventas (NYSE: VTR) and Welltower (NYSE: WELL). However, not all senior housing REITs went the dividend-cut route. LTC Properties (NYSE: LTC) and Omega Healthcare Investors (NYSE: OHI) held their dividends steady. Both have worked with their tenants, including exiting troubled relationships and bringing on new operators. LTC Properties has notably started to include senior housing operating assets (also known as SHOP) in its mix, which means it owns and operates the assets. Of course, each tenant has its own needs, so there were a lot of moving parts, and there's no one-size-fits-all description of what these REITs did. However, the outcome was that they continued to pay their dividends just like they had before the pandemic. Now that the world has learned to live with COVID, these two REITs are set to benefit from serving the housing needs of the oldest people. The demographic future is set to see the ranks of the oldest cohort rise materially in the years ahead. These groups are the ones that need the most assistance with their day-to-day needs. With exposure from nursing homes and well-living, Omega and LTC are worth a close look for high-yield investors today. Their yields are 6.9% and 6.4%, respectively, as I write this. A steadily growing dividend Just holding the line during the pandemic might not be enough for some investors. So, how about a healthcare REIT that has increased its dividend annually for 40 consecutive years? That's exactly the record that Universal Health Realty Trust (NYSE: UHT) has achieved to go along with its ultra-high 7.1% dividend yield. Unlike Omega and LTC Properties, Universal Health Realty's portfolio is focused on medical office properties. There are two caveats here, however. The company's largest tenant is Universal Health Services (NYSE: UHS), which also happens to be the company that manages the REIT. So, it is a controlled entity, and investors would be right to wonder if the decisions being made about the REIT are being made for the benefit of investors or for the benefit of the manager. However, given the reliable dividend growth, it seems like investors are quite important here. That said, dividend growth has historically averaged around 1.5% a year. That's not a particularly large number, which might dissuade dividend growth investors from buying the REIT. But, given the lofty yield, if you are looking to generate as much income as possible today, Universal Health Realty's slow and steady growth might not bother you all that much. Keeping the checks flowing If there's one thing that a dividend investor absolutely hates to see, it is a dividend cut. Despite terrible headwinds, LTC Properties and Omega both avoided doing that, and now they look ready to benefit from an aging population. You can buy around 13 or so shares of either one with $500, or some combination of the two. Universal Health Realty's dividend grew right through the difficult pandemic period, albeit slowly, which many dividend investors will probably find even more appealing. A $500 investment will net you around 12 shares of Universal Health Realty Trust. Do the experts think Omega Healthcare Investors is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Omega Healthcare Investors make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,041% vs. just 183% for the S&P — that is beating the market by 858.71%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 3 Unstoppable Ultra-High-Yield Stocks to Buy Right Now for Less Than $500 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 hours ago
- Yahoo
Patient Monitoring Devices Market Size Expected to Reach USD 123.72 Bn by 2034
The global patient monitoring devices market size is calculated at USD 63.94 billion in 2025 and is expected to reach around USD 123.72 billion by 2034, growing at a CAGR of 7.73% for the forecasted period. Ottawa, July 28, 2025 (GLOBE NEWSWIRE) -- The global patient monitoring devices market size was valued at USD 59.36 billion in 2024 and is predicted to hit around USD 123.72 billion by 2034, a study published by Towards Healthcare a sister firm of Precedence Research. The growth of the market is driven by the growing demand for remote and personalized care with a technologically advanced system, which fuels the growth of the market. Get a quick preview of the key trends and insights shaping the Patient Monitoring Devices Market: Key Takeaways North America dominated the global market in 2024. Asia-Pacific is anticipated to grow at the fastest rate in the patient monitoring devices market during the forecast period. By product, the multi-parameter monitoring devices segment held a dominant presence in the market in 2024. By product, the cardiac monitoring devices segment is predicted to witness significant growth in the market over the forecast period. By end-use, the hospital segment led the global market in 2024. By end-use, the home care settings segment is expected to grow at the fastest rate in the market during the forecast period. Market Overview & Potential A patient monitor is a medical device that tracks, records, and displays a patient's vital signs and other physiological data, offering real-time updates on their health. These devices are essential for continuous monitoring, particularly in critical care environments, allowing healthcare providers to swiftly detect and address any changes in the patient's condition. Common applications include critical care, routine checkups, and remote surveillance. Types of patient monitors range from basic vital sign monitors to advanced multiparameter units and remote monitoring systems. Access comprehensive market data, forecasts, and segment analysis in our exclusive databook: What is the Growth Potential Responsible for the Growth of the Patient Monitoring Devices Market? The global market for patient monitoring devices is growing significantly, fueled by various factors such as the increasing prevalence of chronic diseases like cardiovascular conditions, diabetes, and respiratory illnesses that need ongoing supervision. The aging population, being more susceptible to chronic ailments, amplifies the demand for these devices. Technological progress, especially in wireless and wearable tech, has led to the creation of devices that enable continuous, non-intrusive monitoring. Additionally, the rising use of remote patient monitoring (RPM) helps healthcare providers oversee patients remotely, decreasing hospital visits and costs. Government initiatives like the FCC's COVID-19 Telehealth Program and Rural Health Care Program are also instrumental in expanding RPM access, particularly in underserved regions. What Are the Growing Trends Associated with the Patient Monitoring Devices Market? Remote Patient Monitoring The growing demand for real-time patient monitoring and demand for monitoring devices like mobile devices, virtual care, and wearable sensors increases the growth of the market. AI and ML Integration The growing demand for technologically advanced systems and devices through the integration of AI and ML boosts the growth of the market. Expansion Of Virtual Care The growing demand for telemedicine, digital therapeutics, and remote monitoring for chronic diseases influences the growth of the market. Focus On Chronic Disease Management The growing emphasis and attention on monitoring the growing chronic diseases for the prevention of patient deterioration increases the demand. What Is the Growing Challenge in the Patient Monitoring Devices Market? The patient monitoring devices market encounters various challenges such as data security and privacy issues, high costs, and interoperability problems. The rising adoption of connected devices for patient monitoring amplifies concerns about the security of sensitive patient information. Moreover, market growth can be impeded by difficulties in ensuring patient compliance and engagement, regulatory hurdles, and a shortage of technical expertise. You can place an order or ask any questions, please feel free to contact us at sales@ Regional Analysis How Did North America Dominate the Patient Monitoring Devices Market in 2024? North America dominated the global market in 2024. The region has seen significant growth in the market, the growth is driven by various drivers like such as the growing prevalence of chronic diseases and continuous monitoring of parameters in the aging population, which increases the demand for monitoring devices. Technological advancements for easy handling and patient control system solutions have contributed to the growth of the market and also helped in the expansion of the market in the region. The key players of the region, like 3M, Boston Scientific Corporation, Covidien, Drägerwerk AG and Co. KGaA, GE Healthcare, Medtronic Plc, Mindray Medical, Omron, and Nihon Kohden Corporation, played a crucial role in the growth of the market through their innovation and development of products. U.S. Market Trends The U.S. patient monitoring devices market is seeing steady growth, thanks to strong industry players like Abbott Laboratories, GE Healthcare, and Vesta Healthcare, who currently lead the market. These devices are carefully regulated by the U.S. Food and Drug Administration (FDA), which, as of March 2025, has approved or cleared 188 companion diagnostic devices. In 2024, the U.S. patient monitoring devices market is valued at $21.4 billion and is expected to rise to $23.03 billion in 2025. Looking further ahead, the market is projected to almost double by 2034, reaching approximately $44.68 billion. This growth at an average annual rate of 7.64% from 2025 to 2034 is being fueled by a rising number of chronic disease cases and ongoing innovation in healthcare technology. Access the complete U.S. Patient Monitoring Devices Market report with detailed insights, competitive analysis, and strategic guidance: What Made Asia Pacific Significantly Grow in the Patient Monitoring Devices Market in 2024? Asia-Pacific is anticipated to grow at the fastest rate in the patient monitoring devices market during the forecast period. Asia Pacific is experiencing steady growth in the market, driven by rapid growth in the medical devices sector, with a growing population and growing prevalence of chronic diseases, which require regular monitoring. The key players like GE Healthcare, Omron Healthcare, Medtronic PLC, Boston Scientific Corporation, and Abbott Laboratories play a crucial role in the growth of the market. The change in lifestyle preferences and change in eating habits have led to unhealthy norms, which lead to diseases, and this fuels the growth of the market and contributes to the expansion of the market in the region. According to Volza's Global Export data, the world shipped out 9,018 Patient Monitoring System shipments from October 2023 to September 2024 (TTM). These exports were handled by 601 Indian exporters to 392 buyers, showing a growth rate of 4% over the previous 12 months. Globally, China, the United States, and Germany are the top three exporters of Patient Monitoring Systems. China is the global leader in Patient Monitoring System exports with 23,113 shipments, followed closely by the United States with 19,428 shipments, and Germany in third place with 15,850 shipments. Get the latest insights on life science industry segmentation with our Annual Membership: Segmental Insights By Product Which Product Segment Dominated the Patient Monitoring Devices Market In 2024? The multi-parameter monitoring devices segment held a dominant presence in the market in 2024. The multi-parameter monitoring devices product segment in the patient monitoring device market is experiencing rapid growth, led by highly integrated systems that simultaneously track vital signs like heart rate, SpO₂, respiration, and temperature. These devices, especially portable and wearable ones, offer low-power, compact, and cost-effective solutions for hospitals, home care, and ambulatory settings. Their ability to support remote monitoring, improve clinical decision-making, and enable early warning of patient deterioration is boosting demand, positioning this segment as the largest and most dynamic driver of market expansion. The cardiac monitoring devices segment is predicted to witness significant growth in the market over the forecast period. The cardiac monitoring devices segment plays a vital role in the patient monitoring device market, driven by the growing incidence of heart-related disorders and the need for early diagnosis and continuous care. These devices, such as ECG monitors, Holter monitors, and implantable loop recorders, enable real-time tracking of heart activity, helping detect arrhythmias, heart failure, and other conditions. Their ability to provide accurate, continuous monitoring supports improved clinical outcomes, boosting demand across hospitals, specialty clinics, and homecare settings. By End-Use How Did the Hospital Segment Dominate the Patient Monitoring Devices Market In 2024? The hospital segment led the global market in 2024. The hospital segment is a major end user in the patient monitoring device market, driven by the need for continuous and accurate monitoring of patients in critical care, surgical, and emergency settings. Hospitals rely on a wide range of devices such as multi-parameter monitors, cardiac monitors, and respiratory trackers, to manage patient health and detect complications early. With rising patient admissions and advancements in monitoring technologies, hospitals continue to be a key driver of market demand and growth. The home care settings segment is expected to grow at the fastest rate in the market during the forecast period. The home care settings segment is rapidly growing in the patient monitoring device market, fueled by the increasing shift toward personalized, remote, and cost-effective healthcare. Patients with chronic conditions, post-operative needs, or elderly care requirements benefit from portable and easy-to-use monitoring devices that track vital signs like blood pressure, heart rate, and oxygen levels. These solutions enhance patient comfort, reduce hospital visits, and support early intervention, driving strong adoption and expanding the role of home care in healthcare delivery. Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes schedule a call today: Recent Developments In July 2025, OMRON Healthcare, a global leader in innovative home health monitoring solutions, collaborated with Tricog Health, an AI-driven cardiac care company, to announce the launch of KeeboHealth, an advanced health platform that is designed to transform remote cardiac care and accelerate progress toward OMRON's ambitious 'Going for Zero' vision - a world with zero cardiovascular events. Patient Monitoring Devices Market Key Players List Abbott Laboratories Accuhealth BioIntelliSense Cadence Dexcom, Inc. GE Healthcare Hicuity Health Medical Guardian Nihon Kohden Corporation Omron Corporation Prevounce Health Royal Philips Smart Meter Vesta Healthcare Browse More Global Healthcare Technology Market Overview Patient-Centric Healthcare App MarketThe global market for patient-centric healthcare apps is valued at USD 14.84 billion in 2024 and is expected to grow to USD 17.39 billion by 2025. It is projected to reach approximately USD 72.87 billion by 2034, expanding at a robust CAGR of 17.21% from 2025 to 2034. Therapeutic Drug Monitoring (TDM) MarketThe global TDM market is estimated at USD 1.92 billion in 2024 and is forecasted to rise to USD 1.99 billion by 2025. It is anticipated to reach USD 2.8 billion by 2034, registering a CAGR of 3.84% between 2025 and 2034. Continuous Glucose Monitoring Devices MarketValued at USD 4.97 billion in 2024, the continuous glucose monitoring devices market is expected to grow to USD 5.33 billion in 2025 and approximately USD 9.93 billion by 2034, expanding at a CAGR of 7.22% from 2025 to 2034. Digital Biomarkers MarketThe global digital biomarkers market is valued at USD 5.09 billion in 2025 and is projected to reach around USD 32.37 billion by 2034, witnessing significant growth at a CAGR of 22.74% over the forecast period. Non-Invasive Blood Glucose Monitoring System MarketThe market size for non-invasive blood glucose monitoring systems is estimated at USD 34 million in 2024 and is projected to reach USD 316.65 million by 2034, growing at an impressive CAGR of 25% during the forecast period. Anesthesia Monitoring Devices MarketThe anesthesia monitoring devices market is forecasted to grow from USD 3.17 billion in 2025 to USD 7.16 billion by 2034, registering a CAGR of 9.5% between 2025 and 2034. Blood Pressure Monitoring Devices MarketThe global market for blood pressure monitoring devices is valued at USD 2.30 billion in 2024 and is expected to grow to USD 8.62 billion by 2034, exhibiting a CAGR of 14.1% over the forecast period. Smart Ward MarketThe smart ward market was valued at USD 3.06 billion in 2023 and is projected to reach USD 11.83 billion by 2034, growing at a CAGR of 13.1% from 2024 to 2034. Life Sciences Enterprise Storage MarketThe life sciences enterprise storage market is valued at USD 2.71 billion in 2024 and is expected to grow to USD 2.86 billion in 2025, reaching approximately USD 4.67 billion by 2034 at a CAGR of 5.65% from 2025 to 2034. Pain Management Devices MarketIn 2024, the global pain management devices market is valued at USD 7.68 billion, rising to USD 8.41 billion in 2025, and is anticipated to reach USD 19.1 billion by 2034, growing at a CAGR of 9.54% from 2025 to 2034. Segments Covered in The Report By Product Multi-parameter Monitoring Devices Low-acuity Monitoring Devices Mid-acuity Monitoring Devices High-acuity Monitoring Devices Cardiac Monitoring Devices ECG Devices Implantable Loop Recorders Event Monitors Mobile Cardiac Telemetry Monitors Smart/Wearable ECG Monitors Blood Glucose Monitoring Systems Self-monitoring Blood Glucose Systems Continuous Glucose Monitoring Systems Respiratory Monitoring Devices Pulse Oximeters Spirometers Capnography Peak Flow Meters Temperature Monitoring Devices Handheld Temperature Monitoring Devices Table-top Temperature Monitoring Devices Wearable Continuous Monitoring Devices Invasive Temperature Monitoring Devices Smart Temperature Monitoring Devices Hemodynamic/Pressure Monitoring Devices Hemodynamic Monitors Blood Pressure Monitors Disposables Fetal & Neonatal Monitoring Devices Fetal Monitoring Devices Neonatal Monitoring Devices Neuromonitoring Devices Electroencephalograph Machines Electromyography Machines Cerebral Oximeters Intracranial Pressure Monitors Magnetoencephalograph Machines Transcranial Doppler Machines Weight Monitoring Devices Digital Analog Others By End-Use Hospitals Home Care Settings Ambulatory Surgery Centers Others By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access the complete Patient Monitoring Devices Market report with in-depth analysis, competitive landscape, and strategic recommendations: You can place an order or ask any questions, please feel free to contact us at sales@ Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
